Article Contents ::
- 1 The Brand Name DEZROLALA Has Generic Salt :: Tolterodine
- 2 DEZROLALA Is From Company TAJ PH. Priced :: Rs. 90.20/155.40
- 3 DEZROLALA have Tolterodine is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DEZROLALA Has Generic Salt :: Tolterodine
DEZROLALA Is From Company TAJ PH. Priced :: Rs. 90.20/155.40
DEZROLALA have Tolterodine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Tolterodine | TAB | Rs. 90.20/155.40 | 10-Oct |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10-Oct |
| DEZROLALA | TAJ PH. | 2/4;MG | 10-Oct | Rs. 90.20/155.40 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From TAJ PH. :: DEZROLALA | Tolterodine | #N/A | #N/A |
Indications for Drugs ::
Overactive bladder
Drug Dose ::
Oral Overactive bladder Adult: >18 yr: As immediate release preparation: 2 mg bid, reduce to 1 mg bid if needed to reduce side effects. Reduce to 1 mg bid in patients concurrently taking CYP3A4 inhibitors. As extended release preparation: 4 mg once daily, may reduce to 2 mg daily if needed to reduce side effects. Reduce to 2 mg daily in patients concurrently taking CYP3A4 inhibitors. Renal impairment: CrCl (ml/min) <30 1 mg bid (as immediate-release tablets) or 2 mg once daily (as extended-release capsules). Hepatic impairment: 1 mg bid (as immediate-release tablets) or 2 mg once daily (as extended-release capsules). Contraindication ::
Tolterodine is contraindicated in patients with known hypersensitivity to tolterodine or any other component of the drug, urinary retention and uncontrolled narrow angle glaucoma.
Drug Precautions ::
Tolterodine should be used with caution in the patients at risk for urinary retention & decreased gastrointestinal motility, with impaired renal & hepatic function and with myasthenia gravis.
Drug Side Effects ::
Tolterodine may cause mild-to-moderate antimuscarinic effects, like dryness of the mouth, dyspepsia and reduced lacrimation.
Pregnancy category ::
3
Drug Mode of Action ::
Tolterodine is a competitive muscarinic receptor antagonist with actions similar to atropine. It is used in the management of urge urinary incontinence, urgency and frequency.
Drug Interactions ::
Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of ‘cholinergic neurogenic hypersensitivity’ with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.
